Drugs / XL114
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05144347 | Apr → Nov 2022 | chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma activated B-cell type, mantle cell lymphoma | Exelixis | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-10-14 | Exelixis | Regulatory Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma exelixis.com ↗
Following the U.S. Food and Drug Administration’s (FDA) recent acceptance of its Investigational New Drug (IND) application, Exelixis will soon initiate a phase 1 clinical trial evaluating XL114 monotherapy in patients with Non-Hodgkin’s lymphoma (NHL). |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XL114 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05144347 ↗ |
| Route | Oral | “administered alone orally” NCT05144347 ↗ |